Proteomic analysis of more than 1000 biomarkers from just 4 µL of sample
Olink Reveal, the newest high-throughput proteomics solution, leverages Olink’s established Proximity Extension Assay (PEA) technology with next-generation sequencing (NGS) readouts. Olink Reveal, similar to the Olink Explore platform but with a new, focused assay library and a streamlined workflow, allows researchers to measure over 1,000 proteins from only 4 µL of sample.
Powered by Olink (TM)
Olink’s Proximity Extension Assay (PEA) technology
Minimal Sample Volume (4 μL)
Broad Dynamic Range, down to fg/mL, detecting both high and low abundant proteins
Unmatched Throughput, capable of generating millions of data points per run, supporting large-scale studies
High Specificity & Sensitivity: Dual antibody recognition and barcoding coupled with signal amplification significantly reduces nonspecific signals and false positives
Trusted Technology by the world's leading research institutions and pharmaceutical companies, with over 2,300 publications based on it
PEA technology is an advanced biochemical method that effectively combines the specificity of antibodies with the sensitivity and amplification power of PCR. At the heart of PEA is a mechanism involving two proximity probes, each made up of an antibody attached to a unique DNA oligonucleotide.
When these probes bind to their target protein, they come close together, allowing the DNA oligonucleotides to hybridize and form a double-stranded DNA molecule. This DNA molecule can then be extended by DNA polymerase.
To enable sample multiplexing, unique sample indices are added during a subsequent PCR step. This leads to the creation of a unique DNA sequence that is directly quantifiable using real-time PCR or Next-Generation Sequencing (NGS), translating the protein’s presence into a measurable DNA signal. The NGS counts obtained are proportional to the protein’s concentration in the sample, allowing for its relative quantification.
Olink Reveal’s Powerful Content
Olink Reveal’s powerful content equips users to ask impactful questions that drive meaningful insights.
The Olink Reveal assay library has been meticulously curated to deliver broad pathway coverage, capturing 100% of top biological pathways from Reactome and 64% of all known pathways—along with robust immune response coverage that includes 537 inflammatory markers spanning 96% of immune response pathways.
Olink Reveal’s Broad Coverage of Pathways Supports Discovery:
It also features over 700 proteins with documented cis-pQTLs (genetic variants located near each protein’s encoding gene), providing deeper insights into disease mechanisms. Lastly, the library ensures comprehensive representation of proteins linked to the highest disease risk scores from the UK Biobank proteomics project, enhancing the value of discovery and clinical research.
Olink Reveal Helps Investigate a Wide Range of Disorders:
The Olink Reveal library’s broad coverage opens up a wide spectrum of applications across research and healthcare. By measuring inflammation and immune markers, it offers a powerful tool for studying disease mechanisms and pathophysiology and for identifying key biomarkers of disease progression. Its comprehensive immune profiling capabilities also support personalized medicine by stratifying patients and tracking immune markers during novel therapies. In infectious disease research, Reveal assists in profiling immune responses to bacterial, viral, and fungal pathogens and in monitoring vaccine candidates. In oncology, it helps illuminate the role of inflammation in tumor progression, metastasis, and therapy resistance, as well as supports the monitoring of immune responses during immunotherapy. Chronic disease research similarly benefits by gaining insights into how systemic inflammation exacerbates conditions such as diabetes and cardiovascular disease. Additionally, the library can enrich environmental exposure studies by investigating how external factors influence immune responses, potentially leading to autoimmune diseases and allergies.
Olink Reveal: An Accessible, High-Performance Solution
Olink Reveal is an accessible, cost-effective solution that pairs robust performance with exceptional sensitivity for proteomics analysis. It demonstrates femtogram-per-milliliter (fg/mL) sensitivity and consistently low variation across intra-plate, inter-plate, and inter-site measurements, delivering under 8% CV across different locations. Olink Reveal also shows high concordance (R > 0.94) with Olink Explore. Furthermore, its streamlined setup allows for the simultaneous analysis of 86 samples across more than 1,000 protein targets in a single run—ideal for large-scale cohort studies aiming to uncover disease signatures and inflammation mechanisms.
By offering extensive pathway coverage alongside high data quality at a lower cost, Olink Reveal is poised to drive transformative advances in modern proteomics, paving the way for new biomarker discoveries and accelerating progress in diagnostics and personalized medicine.
How we work
Design the study
Instead of just analyzing your samples, we provide you with a dedicated proteomic specialist who possesses extensive knowledge and ensures that the study design is tailored to your specific requirements and hypothesis.
Send samples
Send your samples to either our European or US dedicated sample collection sites, equipped with state-of-the-art storage infrastructure and monitoring. You can use either our approved carriers or follow your own shipment processes.
Receive report
Obtain a comprehensive proteomic analysis report encompassing the study design, detailed methodology, dataset, visualizations, bioinformatic analysis, and any additional agreed-upon services outlined in the study plan.
Receive consultation
Schedule a one-hour consultation call with our Chief Scientific Officer and our Project Manager to discuss crucial biological discoveries and address any further inquiries you may have for advancing your research to the next level.
Why Protavio?
20+ years of multiplex proteomics experience
GMP, ISO:9001, ISO:13485 compliant processes
Advanced bioinformatic analysis for proteomics
Orthogonal biomarker validation with multiple platforms
The Team
Leonidas Alexopoulos
PhD, Acting CEO, Professor, National Technical University of Athens
Leonidas is one of the pioneers of multiplex assays & systems biology with more than 20 years of experience in the field of proteomics. He has studied at Duke, MIT and Harvard and is currently a professor at National Technical University of Athens. Leonidas co-founded Protavio in 2011 with the ultimate goal of improving people’s health through innovation in proteomics.
Sophia Stamatatou
Co-founder, COO & Quality Director, MSc, MBA
Sophia holds an MSc in Robotics & Automation and an MBA from National Technical University of Athens. Her passion for engineering and entrepreneurship led her to co-found Protavio in 2011. Since 2018, she has held the position of Chief Operating Officer and Quality Director. Her decade long experience of business development and administration make her a key decision maker in Protavio.
Nikos Tsolakos
Chief Scientific Officer, Phd
Nikos holds a PhD from Imperial College London and has over 15 years of work experience in academic and industrial research positions in the field of proteomics. Nikos joined Protavio in 2017 as a Quality Assurance & Project Manager. Since 2023, he holds the position of Chief Scientific Officer to advance Protavio’s proteomic solutions.
Christos Fotis
Chief Innovation Officer, Phd
Christos holds a PhD in AI & Bioinformatics from National Technical University of Athens and has extensive experience in creating and managing R&D projects and consortia. Christos joined Protavio in 2021 as a Research & Innovation manager. Since 2023, he holds the position of Chief Innovation Officer to drive new innovative projects using proteomics.